Skip to content
Screener

Innoviva, Inc. INVA Other Income (Expense)

Other Income (Expense) at other companies

Merck & Co. logo
Merck & Co.MRK
-$99M-1,514%
Insmed logo
InsmedINSM
-$531K-217%
Savara logo
SavaraSVRA
$737K-29.1%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$3.49M+139%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
-$943K-93.2%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$55.71M+1,905%

Other financials

Income statement

See full
Revenue$119.6M+19.3%
Gross profit$90.6M+9.0%
Operating income$50.9M+4.3%
Net income-$83.4M-231%
EPS (diluted)-$1.14-248%

Balance sheet

See full
Cash & equivalents$570.4M+43.5%
Total debt$269.7M-40.2%
Total equity$1.2B
Total assets$1.7B+27.7%

Cash flow

See full
Operating cash flow$52.0M+17.9%
CapEx$429.0K
Free cash flow$51.5M+16.9%

Valuation

See full
Market cap$1.48B+20.6%
Enterprise value$1.18B-7.6%
P/E4.2×-27.6×
P/S3.4×+0.1×

Profitability

See full
Gross margin72.2%-10.9pp
Operating margin36.9%-10.7pp
Net margin81.2%+70.8pp
FCF margin43.1%-11.1pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio16×+13.4×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:26 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335235
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Changes in fair values of equity and long-term investments, net(29,153)11,2804,422(54,019)
Interest and dividend income7,5994,92518,5869,463
Interest expense(5,472)(4,663)(10,909)(9,374)
Other expense, net(15)(777)(381)(1,773)
Income (loss) before income taxes(108,020)72,598126,54334,009
Income tax benefit (expense), net24,600(8,910)(23,368)(16,905)
Net income (loss) and comprehensive income (loss)$(83,420)$63,688$103,175$17,104
Net income (loss) per share:

Item 1. Financial Statements

FAQ

What is Innoviva, Inc.'s other income (expense)?
Innoviva, Inc. (INVA) reported other income (expense) of -$15K in Q2 2026.
How has Innoviva, Inc.'s other income (expense) changed year-over-year?
Innoviva, Inc.'s other income (expense) increased by 98.1% year-over-year, from -$777K to -$15K.
What is the long-term trend for Innoviva, Inc.'s other income (expense)?
Over 4 years (2021 to 2025), Innoviva, Inc.'s other income (expense) has grown at a -5.7% compound annual growth rate (CAGR), from -$3.63M to -$2.86M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about Innoviva, Inc.'s other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude